PCRX vs SUPN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 26, 2026

PCRX

51.3
AI Score
VS
PCRX Wins

SUPN

49.1
AI Score

Investment Advisor Scores

PCRX

51score
Recommendation
HOLD

SUPN

49score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric PCRX SUPN Winner
Forward P/E 8.726 20.1613 PCRX
PEG Ratio 11.2121 1.47 SUPN
Revenue Growth 5.0% 38.6% SUPN
Earnings Growth -30.0% 11.1% SUPN
Tradestie Score 51.3/100 49.1/100 PCRX
Profit Margin 0.7% -3.7% PCRX
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

PCRX 1M: +5.5% · 3M: +3.6% SUPN 1M: -5.9% · 3M: -7.0%

Current Technical Phase

PCRX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 60

RSI (14): 59.9 · Price: $26.41

SUPN

Markdown
Sell / avoid

Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 39

RSI (14): 39.3 · Price: $44.63

Fundamentals Snapshot

Metric PCRX SUPN
Market Cap
Forward P/E 7.2 10.3
Trailing P/E 207.5
Revenue (TTM)
Revenue Growth 0.1% 0.4%
Gross Margin 0.8% 0.7%
Operating Margin 0.0% 0.0%
EPS 0.13 -0.51
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, PCRX is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.